Clinical trials: Demyelinating Disorder
Multiple Sclerosis, MS, Multiple Sclerosis
Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory and disabling disease of the Cnetral Nervous System characterized by relapsing and / or progressive somatosensory, motor and vestibular clinical manifestations.
- Conditions
- Multiple Sclerosis, MS, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- NCT07680738
- Testing
- Transcranial Direct Current Stimulation
- Where
- Mexico
- Volunteers
- 38 people
- Sponsor
- Universidad de Almeria
Multiple Sclerosis
Effects of Resistance Training in Multiple Sclerosis: a Randomized Trial.
This is a longitudinal study to examine the effects of a short-term training program on neurofilamet and GFAP plasma levels. Participants will be divided in two groups: control group (moderate aerobic training) and active group…
- Trial name
- ACTIVE (NCT06478784)
- Testing
- Resistance training, Low aerobic training
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Clínico Universitario de Valladolid
Multiple Sclerosis
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
- Trial name
- SUNBEAM (NCT02294058)
- Testing
- Ozanimod, Interferon beta-1a
- Where
- 224 sites in United States, Belarus and 23 more
- Volunteers
- 1,346 people
- Sponsor
- Celgene
Multiple Sclerosis
Profile of Adherence to Therapy and Interventions to Promote Adherence in MS
Adherence is an active process wherein the patient acts in collaboration with the medical and paramedical staff in order to improve his/her health.
- Trial name
- NCT02488343
- Testing
- Behavioral Intervention
- Where
- Israel
- Volunteers
- 400 people
- Sponsor
- Carmel Medical Center
Multiple Sclerosis (MS)
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to determine if a sequential combination therapy of natalizumab and alemtuzumab induces peripheral tolerance and reduces the annualized relapse rate (ARR) in patients with relapsing-remitting multiple…
- Trial name
- SUPPRESS (NCT03135249)
- Testing
- Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis, Insulin Resistance
Insulin Resistance in Egyptian Patients With Multiple Sclerosis
The goal of this three-phase interventional study is to determine the prevalence of Insulin resistance in non-diabetic patients with multiple sclerosis in Egypt The main questions it aims to answer are: 1.
- Trial name
- IR-MS (NCT06017726)
- Testing
- treatment of insulin resistance with appropriate modality according to each patient
- Volunteers
- 100 people
- Sponsor
- Assiut University
Progressive Multiple Sclerosis
Telerehabilitation in Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a highly disabling chronic, inflammatory, demyelinating disease of the Central Nervous System (CNS). Significant progress has been made during the past three decades in managing the relapsing-remitting…
- Trial name
- NCT06485115
- Testing
- Digital Telerehabilitation (Euleria Home), Conventional therapy
- Where
- Italy
- Volunteers
- 78 people
- Sponsor
- Universita di Verona
Chronic Inflammatory Demyelinating Polyneuropathy
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Participants will be requested to deliver non-invasive vagus nerve stimulation (nVNS) two times per day, at least five days per week.
- Trial name
- NCT03772717
- Testing
- Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
In neuromyelitis optica spectrum disorder (NMOSD),interleukin-6 (IL-6) may play an important role in facilitating plasma cells to produce pathological aquaporin 4 (AQP4) autoantibody.
- Trial name
- TANGO (NCT03350633)
- Testing
- Tocilizumab Injection, Azathioprine
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis (MS) - Relapsing-remitting
Behavioral and Electrophysiological Evidence of the Modulation of Fatigue in RR-MS
To furnish behavioral and electrophysiological evidence of the possible modulation of fatigue in Multiple Sclerosis - relapsing remitting form, through a verbal placebo.
- Trial name
- Fatigue_SM (NCT07624812)
- Testing
- TENS therapy
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Auxologico Italiano
Multiple Sclerosis, Healthy Adult
Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis
The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)
- Trial name
- GAIT-MS (NCT07388992)
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SYSNAV
Multiple Sclerosis
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp.
- Trial name
- NCT04356339
- Testing
- Interferon-beta-1b (BETASERON, BAY 86-5046)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bayer
Late Infantile Metachromatic Leukodystrophy
Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
This is a single center, open-label study of patients with late infantile MLD. All patients were previous treated 26 weeks in the phase I trial (EudraCT number: 2006-005341-11, NCT00418561).
- Trial name
- NCT00633139
- Testing
- Recombinant human Arylsulfatase A (rhASA)
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Shire
Multiple Sclerosis
A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment
This is a multi-center, multi-regional observational,24 month study. Health-related quality of life data from the MusiQoL instrument and SF-36 instrument will be collected at baseline, M6, M12, M18 and M24 in patients with MS.
- Trial name
- MusiQoL (NCT00702065)
- Where
- 30 sites in United States, Argentina and 10 more
- Volunteers
- 599 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Depression
Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis
Cognitive and emotional disorders are often encountered in multiple sclerosis (MS) cases: depressive and bipolar disorders are twice as frequent as in general population.
- Trial name
- SepDep (NCT02468765)
- Testing
- Neuropsychological and emotional evaluation with monitoring
- Where
- France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Lille Catholic University
Multiple Sclerosis
Duloxetine for Multiple Sclerosis Pain
This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple…
- Trial name
- NCT00755807
- Testing
- Duloxetine Hydrochloride (HCI)
- Where
- 22 sites in United States, Belgium and 2 more
- Volunteers
- 239 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
- Trial name
- NCT00336557
- Testing
- NAbs testing
- Where
- 49 sites in United States
- Volunteers
- 1,230 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
- Trial name
- NCT04940065
- Testing
- Kesimpta
- Where
- 103 sites in Japan
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis
Multiple sclerosis is the most common inflammatory disease of the central nervous system and a common cause of disability in young adults.
- Trial name
- NCT04767698
- Testing
- Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Johns Hopkins University
Relapsing Remitting Multiple Sclerosis
PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod
Multi centre, prospective, non interventional study in 200-240 UK relapsing remitting multiple sclerosis patients. Patients will complete questionnaires at baseline, 3, 6 and 12 months.
- Trial name
- PROFILE (NCT02335892)
- Where
- 14 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.